Mainland China funds increase stakes in Hong Kong biotech amid surge of licensing deals
A growing number of mainland Chinese institutional fund managers have built up stakes in Hong Kong-listed biotechnology stocks over the past month, drawn by attractive valuations amid a surge in…
Read the full article
Comments
Sign in to join the conversation.
No comments yet. Be the first.